Clinical Trial Update: Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of dapsone as a second-line option in adults with immune thrombocytopenia; current status is not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• DAPSONE (dapsone)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Adult Immune Thrombocytopenia (ITP), Dapsone | Phase 3 | Status: UNKNOWN